Michelyn Smith, Head of Talent Acquisition at Sarah Cannon Research Institute, shared a post by Vivek Subbiah on LinkedIn:

“When I first joined Sarah Cannon Research Institute (SCRI), I had no idea what a clinical trial was. But over the past year, my perspective has completely changed. Clinical trials are fascinating research studies where individuals volunteer to help find answers to important health questions.

These trials offer a glimmer of hope when standard therapies have fallen short. They provide alternative options for patients who are seeking innovative treatments or are looking to contribute to the advancement of medical knowledge.

Personally, I’ve witnessed the impact of clinical trials on families, as my own loved one has been part of this journey. It’s been truly inspiring to see how these trials have improved her quality of life and brought her renewed hope.

At SCRI, we are at the forefront of groundbreaking research, constantly striving to push the boundaries of medical knowledge. We are committed to providing our patients with access to cutting-edge treatments and therapies through our extensive network of clinical trials.

Let’s spread awareness about clinical trials. Learn more by clicking the link below.”

Quoting Vivek Subbiah’s post:

“Basics About Clinical Trials

Nice link to share for patients and their caregivers.”

Source: Michelyn Smith/LinkedIn and Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.